New tuberculosis drug with proven efficacy tested in Russia
17 April 2017
Infectex, a Russian biomed company, has completed clinical trials for its SQ109 candidate “unparalleled elsewhere in the world,” as the developers say, the Skolkovo Foundation website reported . Infectex claims this is the first new proven drug for tuberculosis in the global market in four decades.
China to tighten rules against faking clinical trial data, criminal charges possible
14 April 2017
Forged clinical trial data have hurt China’s reputation, and the country’s administrative and judicial branches are proposing new actions against such activities in a seemingly synchronized move, and criminal charges are on the table.
Can 2017's top launches hit blockbuster goals? Roche, AstraZeneca, Novo sure hope so
13 April 2017
When it comes to drug launches, who doesn’t love to gaze into a crystal ball? Here at FiercePharmaMarketing, we featured some of those numbers in a special report this February.
U.K. starts handing out £4.7B boost to science funding
13 April 2017
The United Kingdom has unveiled bioscience research investments facilitated by the government’s commitment to provide £4.7 billion ($5.9 billion) more in R&D funding over the next five years. Officials at the Biotechnology and Biological Sciences Research Council (BBSRC) have awarded cash to projects tackling topics including the role of epigenetics and the immune system in aging.
Nine blockbuster drugs to watch are making their debut, aiming at a $16B prize in 2021
12 April 2017
Clarivate Analytics listed the 9 blockbusters their analysts expect to see approved by the FDA this year, and only 4 of them have yet to get the green light in early Q2, including Novo Nordisk’s semaglutide, their GLP-1 drug for diabetes, and AstraZeneca’s PD-L1 checkpoint durvalumab.
Will request for pause in FDA quality metrics plan lead to it being killed as unneeded regulation?
12 April 2017
Tired of dealing with constant, but avoidable, lapses in drug manufacturing, the FDA’s CDER Director Janet Woodcock several years ago decided having drugmakers regularly report quality metrics would help the agency to focus on problem plants before matters got out of control. But even after winning significant revisions to the proposal, the industry is now asking the agency to hit the “pause” button on enactment.
Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer
11 April 2017
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Lorianne K. Masuoka, MD has joined the Company as Chief Medical Officer. Dr. Masuoka is a board certified neurologist with more than 20 years of experience building and expanding high value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances.
Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference
10 April 2017
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented Phase 1 clinical data showing the safety and tolerability of ganaxolone IV, the Company's intravenous formulation of its positive allosteric modulator of GABAA, at the 6th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures in Salzburg, Austria, April 6-8, 2017. Status epilepticus (SE) is a life-threatening medical emergency associated with high mortality and limited treatments. The biennial meeting focuses on highlighting cutting edge research and clinical practice in the field of SE with the aim to lead to improvements in the treatment and outcome of this condition.
U.S. Venture Industry Continues to Normalize as Investors Return to a More Disciplined Approach
10 April 2017
During the first quarter of 2017, investors deployed $16.5 billion to 1,797 venture-backed startups, marking a slight uptick in capital invested over Q4 2016, but the fewest companies to receive investment since Q4 2011, according to the PitchBook-NVCA Venture Monitor. % of dollars in Life Sciences grows to 21,7% of Total US VC. Overall Life Sciences deal % nears seven-year high - 14,8%.
Nanoparticle-delivered combo boosts cancer immunotherapy
10 April 2017
Cancer cells often evade immune attacks by displaying proteins that disguise them as normal. Checkpoint inhibitors block these proteins and reveal tumor cells to the immune system, but they don't work for many patients. Now University of North Carolina researchers have found that using nanoparticles can boost the efficacy of cancer immunotherapy treatments.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024